Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jun 21;3(6):100664.
doi: 10.1016/j.xcrm.2022.100664.

Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting

A Jo Chien  1 , Beverly Kyalwazi  2 , Laura J Esserman  3
Affiliations
Comment

Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting

A Jo Chien et al. Cell Rep Med. .

Abstract

First-line CDK4/6 inhibitor ribociclib plus letrozole improves survival in the metastatic setting, but lack of accrual of African American women is a shortcoming. Predicting benefit in the early-stage setting and diverse enrollment in trials need to be priorities.1.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests. I-SPY2 Trial and EOP is sponsored by the not for profit Quantum Leap Healthcare Collaborative (QLHC). Dr. Esserman is an unpaid board member of QLHC.

Comment on

  • Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
    Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, Campone M, Petrakova K, Winer EP, Janni W, Conte P, Cameron DA, André F, Arteaga CL, Zarate JP, Chakravartty A, Taran T, Le Gac F, Serra P, O'Shaughnessy J. Hortobagyi GN, et al. N Engl J Med. 2022 Mar 10;386(10):942-950. doi: 10.1056/NEJMoa2114663. N Engl J Med. 2022. PMID: 35263519 Clinical Trial.

References

    1. Hortobagyi G.N., Stemmer S.M., Burris H.A., Yap Y.S., Sonke G.S., Hart L., Campone M., Petrakova K., Winer E.P., Janni W., et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N. Engl. J. Med. 2022;386:942–950. doi: 10.1056/nejmoa2114663. - DOI - PubMed
    1. Finn R.S., Martin M., Rugo H.S., Jones S., Im S.A., Gelmon K., Harbeck N., Lipatov O.N., Walshe J.M., Moulder S., et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 2016;375:1925–1936. doi: 10.1056/nejmoa1607303. - DOI - PubMed
    1. Goetz M.P., Toi M., Campone M., Sohn J., Paluch-Shimon S., Huober J., Park I.H., Tredan O., Chen S.C., Manso L., et al. Monarch 3: abemaciclib as initial therapy for advanced breast cancer. J. Clin. Oncol. 2017;35:3638–3646. doi: 10.1200/jco.2017.75.6155. 20171002. - DOI - PubMed
    1. Hortobagyi G.N., Stemmer S.M., Burris H.A., Yap Y.S., Sonke G.S., Paluch-Shimon S., Campone M., Blackwell K.L., Andre F., Winer E.P., et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N. Engl. J. Med. 2016;375:1738–1748. doi: 10.1056/nejmoa1609709. 20161007. - DOI - PubMed
    1. Harbeck N., Rastogi P., Martin M., Tolaney S.M., Shao Z.M., Fasching P.A., Huang C.S., Jaliffe G.G., Tryakin A., Goetz M.P., et al. monarchE Committee Members Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann. Oncol. 2021;32:1571–1581. doi: 10.1016/j.annonc.2021.09.015. 20211014. - DOI - PubMed

MeSH terms